Guidelines for chronic obstructive pulmonary disease
Abstract
Footnotes Competing interests WMcN has been reimbursed by Glaxo-SmithKline, and Boehringer-Ingelheim for attending several conferences. He has been paid for speaking at medical conferences organised by GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim, and Zambon. He has received funding for research from Pfizer, GlaxosmithKline, and SMB Pharmaceuticals but not directly related to any of the drugs discussed in the article.Keywords
This publication has 8 references indexed in Scilit:
- The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2004
- Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care.2004
- Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary diseaseEuropean Respiratory Journal, 2003
- Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 updateEuropean Respiratory Journal, 2003
- Systemic Effects of Chronic Obstructive Pulmonary Disease2000
- Domiciliary oxygen therapy services: clinical guidelines and advice for prescribers. Summary of a report of the Royal College of Physicians.1999
- BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS.1997
- BTS Guidelines for the Management of Chronic Obstructive Pulmonary DiseaseThorax, 1997